Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GeneDx Holdings ( (WGS) ) has issued an announcement.
On January 12, 2026, GeneDx reported preliminary, unaudited 2025 results showing revenues of about $427 million, up 41% year over year, driven by approximately $360 million in exome and genome revenue, which rose 54%, and test volumes that grew more than 30% to 97,271. Fourth quarter 2025 revenues were approximately $121 million, with exome and genome revenues of about $104 million and volume growth accelerating to 34.3%, while GAAP and adjusted gross margins held at about 70% and 71%, respectively, and year-end cash and investments totaled roughly $172 million. Management also issued 2026 guidance calling for revenue between $540 million and $555 million, exome and genome revenue and volume growth of 33% to 35%, adjusted gross margin of at least 70%, and positive adjusted net income, underscoring expectations of continued high growth and improving profitability. Alongside these figures, GeneDx highlighted strategic moves in 2025, including launching its GeneDx Infinity rare disease dataset, expanding into general pediatrics, prenatal diagnostics, and ultra-rapid sequencing, securing broader Medicaid coverage, completing leadership appointments, acquiring Fabric Genomics, and gaining FDA Breakthrough Device designation for key exome and genome tests, all of which reinforce its positioning as a leading player in genomic medicine and newborn screening.
The most recent analyst rating on (WGS) stock is a Buy with a $165.00 price target. To see the full list of analyst forecasts on GeneDx Holdings stock, see the WGS Stock Forecast page.
Spark’s Take on WGS Stock
According to Spark, TipRanks’ AI Analyst, WGS is a Neutral.
GeneDx Holdings demonstrates strong earnings performance and technical momentum, contributing positively to the stock score. However, the extremely high P/E ratio suggests overvaluation, which is a significant risk factor. The earnings call highlights strong revenue growth and technological validation, further supporting a positive outlook.
To see Spark’s full report on WGS stock, click here.
More about GeneDx Holdings
GeneDx Holdings Corp., based in Gaithersburg, Maryland, is a genomics company focused on delivering improved health outcomes through genomic insights, particularly in pediatric and rare diseases. The company provides exome and genome sequencing tests, including rapid and prenatal offerings, and leverages its large GeneDx Infinity dataset and AI‑driven platform to support precision medicine, with a growing presence across pediatric, prenatal, and newborn screening markets in the U.S. and internationally.
Average Trading Volume: 483,524
Technical Sentiment Signal: Buy
Current Market Cap: $3.97B
For detailed information about WGS stock, go to TipRanks’ Stock Analysis page.